Some traders appear to be taking profits off the table after the stock's jump last week.
News & Analysis: Axsome Therapeutics
Demand for Alzheimer's medication is expected to grow as the population of older adults rises.
The drugmaker received good news from the FDA for one of its pipeline candidates.
One big biotech and two small biotechs especially stand out as attractive picks.
The pharmaceutical company appears poised to earn multiple regulatory approvals in 2021. But has too much anticipated success already been priced into its shares?
One biotech has been big long-time winner, the other is a promising up-and-comer with no revenue -- yet. But picking an investment is always a bet on the future.
Just what exactly is going on with this company, which has had success in nearly every single clinical trial it initiated in recent years?
AXSM earnings call for the period ending March 31, 2020.
Competition is about to ramp up significantly in the $1.7 billion market for treating chronic sleep disorder.
Two positive late-stage clinical trials may just be the beginning.